Baidu
map

Am J Kidney Dis:肾脏疾病与静脉血栓栓塞风险之间啥关系?

2017-01-24 xing.T MedSci原创

由此可见,较低的eGFR(<45 vs. ≥90mL/min/1.73 m2)与静脉血栓栓塞风险存在独立的相关性,但ACR和静脉血栓栓塞之间并不存在相关性。

已有研究证实肾脏疾病与静脉血栓栓塞的风险存在相关性,但是这些研究结果存在有冲突的地方,并且有关黑人的研究信息相对较少,近日,肾脏病领域权威杂志Am J Kidney Dis上发表了一篇研究文章,研究者旨在探究肾脏疾病与静脉血栓栓塞风险之间的相关性。

该研究采用前瞻性队列研究设计,主要参与者为参与了REGARDS研究(2003年至2007年脑卒中地理和种族差异的原因研究)的30239名包括黑人和白人的45岁以上成年人。研究人员使用联合肌酐–胱抑素C(eGFRcr-cys)方程和尿白蛋白/肌酐比值(ACR)估算的肾小球滤过率(eGFR)。该研究的主要结局是诊断的静脉血栓栓塞,次要结局为分别为引发的和未引发的静脉血栓栓塞。死亡率作为竞争的风险事件。

在4.6年的随访中,研究人员在124624人次每年的随访中共观察到239次静脉血栓栓塞事件。研究人员采用调整了年龄、性别、种族、居住地区和体重指数的比例风险回归模型计算静脉血栓栓塞特异性风险比。相比于eGFRcr-cys≥90mL/min/1.73 m2,对于eGFRcr-cys60-90mL/min/1.73 m2、45-60mL/min/1.73 m2、<45mL/min/1.73 m2调整的静脉血栓栓塞风险比分别为1.28(95%可信区间为0.94-1.76)、1.30(95%可信区间为0.77-2.18)和2.13(95%可信区间为1.21-3.76)。相比于ACR<10mg/g,对于ACR10-30mg/g、30-300 mg/g和≥300mg/g调整的静脉血栓栓塞风险比分别为1.14(95%可信区间为0.84-1.56)、1.15(95%可信区间为0.79-1.69)和0.64(95%可信区间为0.25-1.62)。而引发的和未引发的静脉血栓栓塞的相关性类似。

由此可见,较低的eGFR(<45 vs. ≥90mL/min/1.73 m2)与静脉血栓栓塞风险存在独立的相关性,但ACR和静脉血栓栓塞之间并不存在相关性。

原始出处:
Katharine L. Cheung,et al. Measures of Kidney Disease and the Risk of Venous Thromboembolism in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis.2017. 

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (23)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1955264, encodeId=c201195526439, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Dec 17 13:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770071, encodeId=162c1e7007147, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Thu May 25 01:18:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697410, encodeId=3214169e410cf, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 19 14:18:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012174, encodeId=02ad20121e47e, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 08 18:18:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602994, encodeId=0d8b1602994f5, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Thu Jan 26 06:18:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172492, encodeId=b9551e24923d, content=如何治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:20 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172491, encodeId=41791e24917c, content=抗凝药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:12 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172490, encodeId=ca461e2490db, content=如何预防, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:57 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172489, encodeId=62821e24897b, content=亚洲的研究在哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:45 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172488, encodeId=83691e2488ea, content=有点意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:24 CST 2017, time=2017-01-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1955264, encodeId=c201195526439, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Dec 17 13:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770071, encodeId=162c1e7007147, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Thu May 25 01:18:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697410, encodeId=3214169e410cf, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 19 14:18:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012174, encodeId=02ad20121e47e, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 08 18:18:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602994, encodeId=0d8b1602994f5, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Thu Jan 26 06:18:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172492, encodeId=b9551e24923d, content=如何治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:20 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172491, encodeId=41791e24917c, content=抗凝药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:12 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172490, encodeId=ca461e2490db, content=如何预防, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:57 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172489, encodeId=62821e24897b, content=亚洲的研究在哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:45 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172488, encodeId=83691e2488ea, content=有点意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:24 CST 2017, time=2017-01-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1955264, encodeId=c201195526439, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Dec 17 13:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770071, encodeId=162c1e7007147, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Thu May 25 01:18:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697410, encodeId=3214169e410cf, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 19 14:18:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012174, encodeId=02ad20121e47e, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 08 18:18:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602994, encodeId=0d8b1602994f5, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Thu Jan 26 06:18:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172492, encodeId=b9551e24923d, content=如何治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:20 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172491, encodeId=41791e24917c, content=抗凝药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:12 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172490, encodeId=ca461e2490db, content=如何预防, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:57 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172489, encodeId=62821e24897b, content=亚洲的研究在哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:45 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172488, encodeId=83691e2488ea, content=有点意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:24 CST 2017, time=2017-01-25, status=1, ipAttribution=)]
    2017-12-19 fusion
  4. [GetPortalCommentsPageByObjectIdResponse(id=1955264, encodeId=c201195526439, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Dec 17 13:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770071, encodeId=162c1e7007147, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Thu May 25 01:18:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697410, encodeId=3214169e410cf, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 19 14:18:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012174, encodeId=02ad20121e47e, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 08 18:18:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602994, encodeId=0d8b1602994f5, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Thu Jan 26 06:18:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172492, encodeId=b9551e24923d, content=如何治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:20 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172491, encodeId=41791e24917c, content=抗凝药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:12 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172490, encodeId=ca461e2490db, content=如何预防, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:57 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172489, encodeId=62821e24897b, content=亚洲的研究在哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:45 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172488, encodeId=83691e2488ea, content=有点意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:24 CST 2017, time=2017-01-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1955264, encodeId=c201195526439, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Dec 17 13:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770071, encodeId=162c1e7007147, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Thu May 25 01:18:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697410, encodeId=3214169e410cf, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 19 14:18:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012174, encodeId=02ad20121e47e, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 08 18:18:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602994, encodeId=0d8b1602994f5, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Thu Jan 26 06:18:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172492, encodeId=b9551e24923d, content=如何治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:20 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172491, encodeId=41791e24917c, content=抗凝药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:12 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172490, encodeId=ca461e2490db, content=如何预防, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:57 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172489, encodeId=62821e24897b, content=亚洲的研究在哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:45 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172488, encodeId=83691e2488ea, content=有点意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:24 CST 2017, time=2017-01-25, status=1, ipAttribution=)]
    2017-01-26 gwc389
  6. [GetPortalCommentsPageByObjectIdResponse(id=1955264, encodeId=c201195526439, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Dec 17 13:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770071, encodeId=162c1e7007147, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Thu May 25 01:18:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697410, encodeId=3214169e410cf, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 19 14:18:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012174, encodeId=02ad20121e47e, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 08 18:18:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602994, encodeId=0d8b1602994f5, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Thu Jan 26 06:18:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172492, encodeId=b9551e24923d, content=如何治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:20 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172491, encodeId=41791e24917c, content=抗凝药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:12 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172490, encodeId=ca461e2490db, content=如何预防, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:57 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172489, encodeId=62821e24897b, content=亚洲的研究在哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:45 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172488, encodeId=83691e2488ea, content=有点意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:24 CST 2017, time=2017-01-25, status=1, ipAttribution=)]
    2017-01-25 yafeiliutjh

    如何治疗

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1955264, encodeId=c201195526439, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Dec 17 13:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770071, encodeId=162c1e7007147, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Thu May 25 01:18:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697410, encodeId=3214169e410cf, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 19 14:18:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012174, encodeId=02ad20121e47e, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 08 18:18:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602994, encodeId=0d8b1602994f5, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Thu Jan 26 06:18:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172492, encodeId=b9551e24923d, content=如何治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:20 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172491, encodeId=41791e24917c, content=抗凝药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:12 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172490, encodeId=ca461e2490db, content=如何预防, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:57 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172489, encodeId=62821e24897b, content=亚洲的研究在哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:45 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172488, encodeId=83691e2488ea, content=有点意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:24 CST 2017, time=2017-01-25, status=1, ipAttribution=)]
    2017-01-25 yafeiliutjh

    抗凝药物

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1955264, encodeId=c201195526439, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Dec 17 13:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770071, encodeId=162c1e7007147, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Thu May 25 01:18:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697410, encodeId=3214169e410cf, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 19 14:18:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012174, encodeId=02ad20121e47e, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 08 18:18:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602994, encodeId=0d8b1602994f5, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Thu Jan 26 06:18:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172492, encodeId=b9551e24923d, content=如何治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:20 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172491, encodeId=41791e24917c, content=抗凝药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:12 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172490, encodeId=ca461e2490db, content=如何预防, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:57 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172489, encodeId=62821e24897b, content=亚洲的研究在哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:45 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172488, encodeId=83691e2488ea, content=有点意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:24 CST 2017, time=2017-01-25, status=1, ipAttribution=)]
    2017-01-25 yafeiliutjh

    如何预防

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1955264, encodeId=c201195526439, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Dec 17 13:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770071, encodeId=162c1e7007147, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Thu May 25 01:18:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697410, encodeId=3214169e410cf, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 19 14:18:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012174, encodeId=02ad20121e47e, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 08 18:18:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602994, encodeId=0d8b1602994f5, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Thu Jan 26 06:18:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172492, encodeId=b9551e24923d, content=如何治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:20 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172491, encodeId=41791e24917c, content=抗凝药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:12 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172490, encodeId=ca461e2490db, content=如何预防, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:57 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172489, encodeId=62821e24897b, content=亚洲的研究在哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:45 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172488, encodeId=83691e2488ea, content=有点意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:24 CST 2017, time=2017-01-25, status=1, ipAttribution=)]
    2017-01-25 yafeiliutjh

    亚洲的研究在哪里

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1955264, encodeId=c201195526439, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Dec 17 13:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770071, encodeId=162c1e7007147, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Thu May 25 01:18:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697410, encodeId=3214169e410cf, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 19 14:18:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012174, encodeId=02ad20121e47e, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 08 18:18:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602994, encodeId=0d8b1602994f5, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Thu Jan 26 06:18:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172492, encodeId=b9551e24923d, content=如何治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:20 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172491, encodeId=41791e24917c, content=抗凝药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:17:12 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172490, encodeId=ca461e2490db, content=如何预防, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:57 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172489, encodeId=62821e24897b, content=亚洲的研究在哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:45 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172488, encodeId=83691e2488ea, content=有点意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Wed Jan 25 09:16:24 CST 2017, time=2017-01-25, status=1, ipAttribution=)]
    2017-01-25 yafeiliutjh

    有点意思

    0

相关资讯

PLoS One:卒中患者,发生肾脏疾病的风险更大

背景:卒中和肾脏疾病之间的相关性的信息较少。研究者旨在调查卒中对长期肾功能的影响。方法: 在这项基于人口的回顾性队列研究中,研究者从2000年1月1号到2012年12月31号,确定了在台湾全民健康保险研究数据库登记的100353例受试者,包括33451例脑卒中患者和66902例,按照年龄、性别和Charlson合并症指数相匹配的对照组。结果: 卒中组比对照组患者,慢性肾脏疾病(CKD)的发病率更高

JASN:在中国,空气污染可增加肾脏疾病风险

众所周知空气污染会导致呼吸系统和心血管疾病,一项新的研究表明,它也有可能导致肾脏损伤。该研究即将发表在杂志肾脏病协会(JASN)杂志上,呼吁关注空气污染在城市地区的肾脏病发展中的作用。空气污染已成为中国许多城市的一个严重问题,但其对个人健康的影响程度尚不清楚。该研究的目的是探讨空气中的颗粒物如何影响肾脏健康,由Fan Fan Hou博士(南方医科大学,广州,中国)领导的研究小组分析了来自中国282

JASN:肾脏疾病患者,严格控制血压更长寿

对于慢性肾脏疾病患者,严格控制血压可能有助于防止过早死亡。这是一个最近的临床试验数据的分析得出的结论。这一发现刊登在即将发行的美国肾脏病学会(JASN)杂志上。血压治疗目标是一个持久辩论的主题。近些年一些随访患者几年的临床试验已经表明,当收缩压较低,为<120mm Hg时(低于目前推荐的目标),对于心脏健康和长寿是有益的。另一方面,一些长期观察研究表明,降低血压水平可能是有害的。为了更好地考

Am J Kidney Dis:防止高血压的膳食能预防肾脏疾病吗?

DASH饮食习惯与降低的肾脏疾病低风险有关,并且独立于人口学特征、已经明确的肾脏的危险因素和肾脏基础功能。健康的饮食模式,如DASH饮食可能有利于肾脏疾病的预防。

重磅!勃林格-礼来降糖药Jardiance在确诊心血管疾病的2型糖尿病患者中显著延缓肾病进展风险

勃林格殷格翰-礼来糖尿病联盟近日在美国新奥尔良举行的2016年第76届美国糖尿病协会(ADA)科学会议(2016年06月10日-14日)上公布了糖尿病药物Jardiance(empagliflozin,恩格列净)里程碑意义的临床研究(EMPA-REG OUTCOME)新的分析数据。数据显示,在确诊心血管(CV)疾病的2型糖尿病成人患者中,与安慰剂+标准护理(包括降糖药和CV药物)相比,Jard

NEJM:Empagliflozin可延缓2型糖尿病患者肾脏疾病的进展

糖尿病增加了不良心血管和肾脏事件的风险。在EMPA-REG观察性试验中,empagliflozin,钠-葡萄糖协同转运蛋白2的抑制剂,可以降低具有心血管事件高风险的2型糖尿病患者的重大不良心血管事件。研究人员想要确定empagliflozin对肾功能的长期影响,这是该试验二次微血管结果的预先规定的分析。研究人员随机分配2型糖尿病患者,估计其肾小球滤过率至少为每分钟30ml每1.73m2体表面积,每

Baidu
map
Baidu
map
Baidu
map